Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - tolterodine tartrate 1mg equivalent to tolterodine 0.68 mg - film coated tablet - 1 mg - active: tolterodine tartrate 1mg equivalent to tolterodine 0.68 mg excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose opadry white 03f58763 purified water   sodium starch glycolate - arrow – tolterodine 1 & arrow tolterodine 2 are indicated for the treatment of overactive bladder with symptoms of urinary urgency, frequency, and/or urge incontinence.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - tolterodine tartrate 2mg equivalent to tolterodine 1.37 mg - film coated tablet - 2 mg - active: tolterodine tartrate 2mg equivalent to tolterodine 1.37 mg excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose opadry white 03f58763 purified water   sodium starch glycolate - arrow – tolterodine 1 & arrow tolterodine 2 are indicated for the treatment of overactive bladder with symptoms of urinary urgency, frequency, and/or urge incontinence.

Bandaríkin - enska - NLM (National Library of Medicine)

teva pharmaceuticals usa inc - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 1 mg - tolterodine tartrate tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. tolterodine tartrate tablets are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate is also contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate, are metabolized to 5- hydroxymethyl tolterodine.

Bandaríkin - enska - NLM (National Library of Medicine)

teva pharmaceuticals usa inc - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14) ] . tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [see warnings and precautions (5.2) (5.3), (5.4) ]. risk summary there are no available data with tolterodine tartrate extended-release capsules use in pregnant women to inform drug-associated risks. in animal reproduction studies, oral administration of tolterodine and its 5-hmt metabolite to pregnant mice during organogenesis did not produce adverse deve

Bandaríkin - enska - NLM (National Library of Medicine)

torrent pharmaceuticals limited - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies ( 14)]. tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [ see warnings and precautions ( 5.2), ( 5.3), ( 5.4) ] . risk summary there are no available data with tolterodine tartrate extended-release capsules use in pregnant women to inform drug-associated risks. in animal

Bandaríkin - enska - NLM (National Library of Medicine)

major pharmaceuticals - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies ( 14)]. tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [ see warnings and precautions ( 5.2), ( 5.3), ( 5.4) ] . risk summary there are no available data with tolterodine tartrate extended-release capsules use in pregnant women to inform drug-associated risks. in animal

Bandaríkin - enska - NLM (National Library of Medicine)

american health packaging - tolterodine tartrate (unii: 5t619tqr3r) (tolterodine - unii:whe7a56u7k) - tolterodine tartrate 2 mg - tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see clinical studies (14) ]. tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [see warnings and precautions (5.2), (5.3), (5.4) ]. risk summary there are no available data with tolterodine tartrate extended-release capsules use in pregnant women to inform drug-associated risks. in animal reproduction studies, oral administration of tolterodine and its 5-hmt metabolite to pregnant mice during organogenesis di

Holland - hollenska - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sandoz b.v. veluwezoom 22 1327 ah almere - tolterodinetartraat 1 mg/stuk samenstelling overeenkomend met ; tolterodine 0,68 mg/stuk - filmomhulde tablet - calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460(i)) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; siliciumdioxide (e 551) ; stearinezuur (e 570) ; titaandioxide (e 171), calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; siliciumdioxide (e 551) ; stearinezuur (e 570) ; titaandioxide (e 171), calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468) ; siliciumdioxide (e 551) ; stearinezuur (e 570) ; titaandioxide (e 171), - tolterodine

Holland - hollenska - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

sandoz b.v. veluwezoom 22 1327 ah almere - tolterodinetartraat 2 mg/stuk samenstelling overeenkomend met ; tolterodine 1,68 mg/stuk - filmomhulde tablet - calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460(i)) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; siliciumdioxide (e 551) ; stearinezuur (e 570) ; titaandioxide (e 171), calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; siliciumdioxide (e 551) ; stearinezuur (e 570) ; titaandioxide (e 171), calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468) ; siliciumdioxide (e 551) ; stearinezuur (e 570) ; titaandioxide (e 171), - tolterodine

Holland - hollenska - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

accord healthcare b.v. winthontlaan 200 3526 kv utrecht - tolterodinetartraat 1 mg/stuk samenstelling overeenkomend met ; tolterodine 0,68 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460(i)) ; hypromellose (e 464) ; macrogol 8000 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; hypromellose (e 464) ; macrogol 8000 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; hypromellose (e 464) ; macrogol 8000 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat (e468) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171), - tolterodine